167 related articles for article (PubMed ID: 3397768)
1. Human central nervous system and plasma pharmacology of mitoxantrone.
Green RM; Stewart DJ; Hugenholtz H; Richard MT; Thibault M; Montpetit V
J Neurooncol; 1988; 6(1):75-83. PubMed ID: 3397768
[TBL] [Abstract][Full Text] [Related]
2. Human autopsy tissue concentrations of mitoxantrone.
Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration.
Czejka MJ; Jäger W; Georgopoulos A; Schüller J
Eur J Drug Metab Pharmacokinet; 1990; 15(3):219-22. PubMed ID: 2253652
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of mitoxantrone. A review.
Ehninger G; Schuler U; Proksch B; Zeller KP; Blanz J
Clin Pharmacokinet; 1990 May; 18(5):365-80. PubMed ID: 2185907
[TBL] [Abstract][Full Text] [Related]
5. Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis.
Boros L; Cacek T; Pine RB; Battaglia AC
Cancer Chemother Pharmacol; 1992; 31(1):57-60. PubMed ID: 1458559
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
7. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Schleyer E; Kamischke A; Kaufmann CC; Unterhalt M; Hiddemann W
Leukemia; 1994 Mar; 8(3):435-40. PubMed ID: 8127148
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.
Nagel JD; Varossieau FJ; Dubbelman R; ten Bokkel Huinink WW; McVie JG
Cancer Chemother Pharmacol; 1992; 29(6):480-4. PubMed ID: 1568292
[TBL] [Abstract][Full Text] [Related]
9. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.
Stewart DJ; Richard MT; Hugenholtz H; Dennery JM; Belanger R; Gerin-Lajoie J; Montpetit V; Nundy D; Prior J; Hopkins HS
J Neurooncol; 1984; 2(2):133-9. PubMed ID: 6481426
[TBL] [Abstract][Full Text] [Related]
10. Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).
Savaraj N; Lu K; Feun LG; Leavens ME; Stewart D; Burgess MA; Benjamin RS; Loo TL
J Neurooncol; 1983; 1(1):15-9. PubMed ID: 6678302
[TBL] [Abstract][Full Text] [Related]
11. Concentration of vinblastine in human intracerebral tumor and other tissues.
Stewart DJ; Lu K; Benjamin RS; Leavens ME; Luna M; Yap HY; Loo TL
J Neurooncol; 1983; 1(2):139-44. PubMed ID: 6678966
[TBL] [Abstract][Full Text] [Related]
12. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.
DiMeco F; Li KW; Tyler BM; Wolf AS; Brem H; Olivi A
J Neurosurg; 2002 Nov; 97(5):1173-8. PubMed ID: 12450040
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.
Richard B; Launay-Iliadis MC; Iliadis A; Just-Landi S; Blaise D; Stoppa AM; Viens P; Gaspard MH; Maraninchi D; Cano JP
Br J Cancer; 1992 Mar; 65(3):399-404. PubMed ID: 1558794
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Schwendener RA; Fiebig HH; Berger MR; Berger DP
Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma.
Hu OY; Chang SP; Law CK; Jian JM; Chen KY
Cancer; 1992 Feb; 69(4):847-53. PubMed ID: 1735075
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
Krukemeyer MG; Krenn V; Jakobs M; Wagner W
J Surg Res; 2012 Jun; 175(1):35-43. PubMed ID: 21470623
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration.
Alberts DS; Surwit EA; Peng YM; McCloskey T; Rivest R; Graham V; McDonald L; Roe D
Cancer Res; 1988 Oct; 48(20):5874-7. PubMed ID: 3167842
[TBL] [Abstract][Full Text] [Related]
18. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
Patel KJ; Trédan O; Tannock IF
Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
[TBL] [Abstract][Full Text] [Related]
19. Brain tissue concentration of mitoxantrone in the rat in relation to in vitro chemosensitivity of malignant human intracranial tumors--preliminary results.
Tonn JC; Schönmayr R; Braun R; Kraemer HP; Ehninger G
J Chemother; 1989 Jul; 1(4 Suppl):1181-2. PubMed ID: 16312824
[No Abstract] [Full Text] [Related]
20. Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas.
Canal P; Attal M; Chatelut E; Guichard S; Huguet F; Muller C; Schlaifer D; Laurent G; Houin G; Bugat R
Cancer Res; 1993 Oct; 53(20):4850-4. PubMed ID: 8402672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
